{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T02:23:56Z","timestamp":1784514236819,"version":"3.55.0"},"reference-count":67,"publisher":"Bentham Science Publishers Ltd.","issue":"8","funder":[{"DOI":"10.13039\/100010661","name":"European Union Horizon 2020 SALSETH research project and innovation program","doi-asserted-by":"publisher","award":["872370"],"award-info":[{"award-number":["872370"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDR"],"published-print":{"date-parts":[[2020,9,11]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Recent studies have suggested that hyperglycaemia influences the bile acid\nprofile and concentrations of secondary bile acids in the gut.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Introduction:<\/jats:title>\n<jats:p>This study aimed to measure changes in the bile acid profile in the gut, tissues, and faeces\nin type 1 Diabetes (T1D) and Type 2 Diabetes (T2D).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Method:<\/jats:title>\n<jats:p>T1D and T2D were established in a mouse model. Twenty-one seven-weeks old balb\/c mice\nwere randomly divided into three equal groups, healthy, T1D and T2D. Blood, tissue, urine and faeces\nsamples were collected for bile acid measurements.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Compared with healthy mice, T1D and T2D mice showed lower levels of the primary bile\nacid, chenodeoxycholic acid, in the plasma, intestine, and brain, and higher levels of the secondary bile\nacid, lithocholic acid, in the plasma and pancreas. Levels of the bile acid ursodeoxycholic acid were\nundetected in healthy mice but were found to be elevated in T1D and T2D mice.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Bile acid profiles in other organs were variably influenced by T1D and T2D development,\nwhich suggests similarity in effects of T1D and T2D on the bile acid profile, but these effects were not\nalways consistent among all organs, possibly since feedback mechanisms controlling enterohepatic recirculation\nand bile acid profiles and biotransformation are different in T1D and T2D.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389450121666200204115121","type":"journal-article","created":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T12:34:00Z","timestamp":1580819640000},"page":"900-909","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Modulatory Nano\/Micro Effects of Diabetes Development on Pharmacology of Primary and Secondary Bile Acids Concentrations"],"prefix":"10.2174","volume":"16","author":[{"given":"Armin","family":"Mooranian","sequence":"first","affiliation":[{"name":"Biotechnology and Drug Development Research Laboratory, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nassim","family":"Zamani","sequence":"additional","affiliation":[{"name":"Biotechnology and Drug Development Research Laboratory, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryu","family":"Takechi","sequence":"additional","affiliation":[{"name":"School of Public Health, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Luna","sequence":"additional","affiliation":[{"name":"Biotechnology and Drug Development Research Laboratory, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momir","family":"Mikov","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Golo\u010dorbin-Kon","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bozica","family":"Kovacevic","sequence":"additional","affiliation":[{"name":"Biotechnology and Drug Development Research Laboratory, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Arfuso","sequence":"additional","affiliation":[{"name":"Stem Cell and Cancer Biology Laboratory, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0049-6969","authenticated-orcid":true,"given":"Hani","family":"Al-Salami","sequence":"additional","affiliation":[{"name":"Biotechnology and Drug Development Research Laboratory, School of Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/BF03190714","volume":"31(3)","author":"Mikov,M.","year":"2006","unstructured":"Mikov,M.; Fawcett,JP.; Kuhajda,K.; Kevresan,S. Pharmacology of bile acids and their derivatives: absorption promoters and therapeu-tic agents. Eur J Drug Metab Pharmacokinet. 2006; 31(3): 237-51. http:\/\/dx.doi.org\/10.1007\/BF03190714 PMID: 17136862","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/BF03190710","volume":"31(3)","author":"Kuhajda,K.","year":"2006","unstructured":"Kuhajda,K.; Kandrac,J.; Kevresan,S.; Mikov,M.; Fawcett,JP. Struc-ture and origin of bile acids: an overview. Eur J Drug Metab Phar-macokinet. 2006; 31(3): 135-43. http:\/\/dx.doi.org\/10.1007\/BF03190710 PMID: 17136858","journal-title":"Eur J Drug Metab Phar-macokinet"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/BF03191110","volume":"33(3)","author":"Mikov,M.","year":"2008","unstructured":"Mikov,M.; Al-Salami,H.; Golocorbin-Kon,S.; Skrbic,R.; Raskovic,A.; Fawcett,JP. The influence of 3alpha, 7alpha-dihydroxy-12-keto-5beta-cholanate on gliclazide pharmacokinetics and glucose levels in a rat model of diabetes. Eur J Drug Metab Pharmacokinet. 2008; 33(3): 137-42. http:\/\/dx.doi.org\/10.1007\/BF03191110 PMID: 19007038","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"ref=4","author":"Mikov,MA-SH. .","unstructured":"Mikov,MA-SH.; Golocorbin-Kon,G. Potentials and Limitations of Bile Acids and Probiotics in Diabetes Mellitus. 2012;,365-402."},{"key":"ref=5","first-page":"49","volume":"1(2)","author":"Negrulj,R.","year":"2013","unstructured":"Negrulj,R.; Mooranian,A.; Al-Salami,H. Potentials and Limitations of Bile Acids in Type 2 Diabetes Mellitus: Applications of Micro-encapsulation as a Novel Oral Delivery System. J Endocrinol Dia-betes Mellit. 2013; 1(2): 49-59","journal-title":"J Endocrinol Dia-betes Mellit"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s12247-014-9182-5","volume":"9(2)","author":"Mooranian,A.","year":"2014","unstructured":"Mooranian A, Negrulj R, Mathavan S.;et al. Stability and Release Kinetics of an Advanced Gliclazide-Cholic Acid Formulation: The Use of Artificial-Cell Microencapsulation in Slow Release Tar-geted Oral Delivery of Antidiabetics. J Pharm Innov. 2014; 9(2): 150-7. http:\/\/dx.doi.org\/10.1007\/s12247-014-9182-5 PMID: 24829616","journal-title":"J Pharm Innov"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1208\/s12249-014-0205-9","volume":"16(1)","author":"Mooranian,A.","year":"2015","unstructured":"Mooranian A, Negrulj R, Al-Sallami HS.;et al. Probucol release from novel multicompartmental microcapsules for the oral targeted delivery in type 2 diabetes. AAPS PharmSciTech. 2015; 16(1): 45-52. http:\/\/dx.doi.org\/10.1208\/s12249-014-0205-9 PMID: 25168450","journal-title":"AAPS PharmSciTech"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"702","DOI":"10.3109\/10837450.2014.915570","volume":"20(6)","author":"Mooranian,A.","year":"2015","unstructured":"Mooranian A, Negrulj R, Mathavan S.;et al. An advanced microen-capsulated system: a platform for optimized oral delivery of an-tidiabetic drug-bile acid formulations. Pharm Dev Technol. 2015; 20(6): 702-9. http:\/\/dx.doi.org\/10.3109\/10837450.2014.915570 PMID: 24798888","journal-title":"Pharm Dev Technol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12668-016-0198-9","volume":"6(2)","author":"Mooranian,A.","year":"2016","unstructured":"Mooranian,A.; Negrulj,R.; Al-Salami,H. Primary bile acid chenode-oxycholic acid-based microcapsules to examine beta-cell survival and the inflammatory response. Bionanoscience. 2016; 6(2): 103-9. http:\/\/dx.doi.org\/10.1007\/s12668-016-0198-9","journal-title":"Bionanoscience"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1080\/02652048.2016.1228703","volume":"33(6)","author":"Mooranian,A.","year":"2016","unstructured":"Mooranian,A.; Negrulj,R.; Al-Salami,H. The impact of allylamine-bile acid combinations on cell delivery microcapsules in diabetes. J Microencapsul. 2016; 33(6): 569-74. http:\/\/dx.doi.org\/10.1080\/02652048.2016.1228703 PMID: 27574968","journal-title":"J Microencapsul"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"S748","DOI":"10.1080\/21691401.2018.1511572","volume":"46(sup3)","author":"Mooranian,A.","year":"2018","unstructured":"Mooranian A, Zamani N, Takechi R.;et al. Pharmacological effects of nanoencapsulation of human-based dosing of probucol on ratio of secondary to primary bile acids in gut, during induction and pro-gression of type 1 diabetes. Artif Cells Nanomed Biotechnol. 2018; 46(sup3): S748-54. http:\/\/dx.doi.org\/10.1080\/21691401.2018.1511572 PMID: 30422681","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"811","DOI":"10.4155\/tde-2018-0036","volume":"9(11)","author":"Mooranian,A.","year":"2018","unstructured":"Mooranian A, Zamani N, Mikov M.;et al. Eudragit \u00ae-based micro-capsules of probucol with a gut-bacterial processed secondary bile acid. Ther Deliv. 2018; 9(11): 811-21. http:\/\/dx.doi.org\/10.4155\/tde-2018-0036 PMID: 30444461","journal-title":"Ther Deliv"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"S741","DOI":"10.1080\/21691401.2018.1511571","volume":"46(sup3)","author":"Mooranian,A.","year":"2018","unstructured":"Mooranian A, Zamani N, Mikov M.;et al. Novel nano-encapsulation of probucol in microgels: scanning electron micro-graph characterizations, buoyancy prof iling, and antioxidant assay analyses. Artif Cells Nanomed Biotechnol. 2018; 46(sup3): S741-7. http:\/\/dx.doi.org\/10.1080\/21691401.2018.1511571 PMID: 30260253","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/10837450.2017.1321664","volume":"23(2)","author":"Mooranian,A.","year":"2018","unstructured":"Mooranian,A.; Takechi,R.; Jamieson,E.; Morahan,G.; Al-Salami,H. The effect of molecular weights of microencapsulating polymers on viability of mouse-cloned pancreatic \u00df-cells: biomaterials, osmotic forces and potential applications in diabetes treatment. Pharm Dev Technol. 2018; 23(2): 145-50. http:\/\/dx.doi.org\/10.1080\/10837450.2017.1321664 PMID: 28425308","journal-title":"Pharm Dev Technol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s13346-017-0473-5","volume":"8(3)","author":"Mooranian,A.","year":"2018","unstructured":"Mooranian,A.; Negrulj,R.; Takechi,R.; Mamo,J.; Al-Sallami,H.; Al-Salami,H. The biological effects of the hypolipidaemic drug probu-col microcapsules fed daily for 4 weeks, to an insulin-resistant mouse model: potential hypoglycaemic and anti-inflammatory ef-fects. Drug Deliv Transl Res. 2018; 8(3): 543-51. http:\/\/dx.doi.org\/10.1007\/s13346-017-0473-5 PMID: 29313296","journal-title":"Drug Deliv Transl Res"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1080\/21691401.2017.1362416","volume":"46(6)","author":"Mooranian,A.","year":"2018","unstructured":"Mooranian,A.; Negrulj,R.; Takechi,R.; Jamieson,E.; Morahan,G.; Al-Salami,H. Electrokinetic potential-stabilization by bile acid-microencapsulating formulation of pancreatic \u00df-cells cultured in high ratio poly-L-ornithine-gel hydrogel colloidal dispersion: ap-plications in cell-biomaterials, tissue engineering and biotechno-logical applications. Artif Cells Nanomed Biotechnol. 2018; 46(6): 1156-62. http:\/\/dx.doi.org\/10.1080\/21691401.2017.1362416 PMID: 28776395","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"ref=17","author":"Mamo,JC.","unstructured":"Mamo JC, Lam V, Brook E, Mooranian A, Al-Salami H, Fimog-nari N.;et al. Probucol prevents blood-brain barrier dysfunction and cognitive decline in mice maintained on pro-diabetic diet. Diabetes & vascular disease research. 2018; 1479164118795274"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"703","DOI":"10.4155\/tde-2018-0033","volume":"9(10)","author":"Mamo,JC.","year":"2018","unstructured":"Mamo JC, Lam V, Al-Salami H.;et al. Sodium alginate capsulation increased brain delivery of probucol and suppressed neuroinflam-mation and neurodegeneration. Ther Deliv. 2018; 9(10): 703-9. http:\/\/dx.doi.org\/10.4155\/tde-2018-0033 PMID: 30277134","journal-title":"Ther Deliv"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"399.","DOI":"10.3389\/fnagi.2017.00399","volume":"9","author":"Takechi,R.","year":"2017","unstructured":"Takechi R, Lam V, Brook E.;et al. Blood-brain barrier dysfunction precedes cognitive decline and neurodegeneration in diabetic insu-lin resistant mouse model: An implication for causal link. Front Aging Neurosci. 2017; 9: 399. http:\/\/dx.doi.org\/10.3389\/fnagi.2017.00399 PMID: 29249964","journal-title":"Front Aging Neurosci"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s11095-017-2138-y","volume":"34(6)","author":"Mooranian,A.","year":"2017","unstructured":"Mooranian,A.; Tackechi,R.; Jamieson,E.; Morahan,G.; Al-Salami,H. Innovative microcapsules for pancreatic \u00df-cells harvested from ma-ture double-transgenic mice: Cell imaging, viability, i nduced glu-cose-stimulated insulin measurements and proinflammatory cyto-kines analysis. Pharm Res. 2017; 34(6): 1217-23. http:\/\/dx.doi.org\/10.1007\/s11095-017-2138-y PMID: 28289997","journal-title":"Pharm Res"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"833","DOI":"10.4155\/tde-2017-0042","volume":"8(10)","author":"Mooranian,A.","year":"2017","unstructured":"Mooranian,A.; Negrulj,R.; Takechi,R.; Jamieson,E.; Morahan,G.; Al-Salami,H. Alginate-combined cholic acid increased insulin secre-tion of microencapsulated mouse cloned pancreatic \u00df cells. Ther Deliv. 2017; 8(10): 833-42. http:\/\/dx.doi.org\/10.4155\/tde-2017-0042 PMID: 28944743","journal-title":"Ther Deliv"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s12195-017-0510-y","volume":"11(1)","author":"Mooranian,A.","year":"2017","unstructured":"Mooranian,A.; Negrulj,R.; Takechi,R.; Jamieson,E.; Morahan,G.; Al-Salami,H. Influence of biotechnological processes, speed of formu-lation flow and cellular concurrent stream-integration on insulin production from \u00df-cells as a result of co-encapsulation with a highly lipophilic bile acid. Cell Mol Bioeng. 2017; 11(1): 65-75. http:\/\/dx.doi.org\/10.1007\/s12195-017-0510-y PMID: 31719879","journal-title":"Cell Mol Bioeng"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1021\/acs.molpharmaceut.7b00220","volume":"14(8)","author":"Mooranian,A.","year":"2017","unstructured":"Mooranian,A.; Negrulj,R.; Takechi,R.; Jamieson,E.; Morahan,G.; Al-Salami,H. New biotechnological microencapsulating methodology utilizing individualized gradient-screened jet laminar flow tech-niques for pancreatic \u00df-cell delivery: bile acids support cell energy-generating mechanisms. Mol Pharm. 2017; 14(8): 2711-8. http:\/\/dx.doi.org\/10.1021\/acs.molpharmaceut.7b00220 PMID: 28682620","journal-title":"Mol Pharm"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2174\/1573399812666151229101756","volume":"13(1)","author":"Mooranian,A.","year":"2017","unstructured":"Mooranian,A.; Negrulj,R.; Al-Salami,H. The effects of ionic gela-tion-vibrational jet flow technique in fabrication of microcapsules incorporating \u03b2-cell: applications in diabetes. Curr Diabetes Rev. 2017; 13(1): 91-6. http:\/\/dx.doi.org\/10.2174\/1573399812666151229101756 PMID: 26710877","journal-title":"Curr Diabetes Rev"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1038\/ijo","volume":"41(6)","author":"Mamo,JCL.","year":"2017","unstructured":"Mamo JCL, Lam V, Giles C.;et al. Antihypertensive agents do not prevent blood-brain barrier dysfunction and cognitive deficits in dietary-induced obese mice. Int J Obes. 2017; 41(6): 926-34. http:\/\/dx.doi.org\/10.1038\/ijo. 2017.57 PMID: 28239165","journal-title":"Int J Obes"},{"key":"ref=26","first-page":"28","volume":"125(1)","author":"Al-Salami H","year":"2017","unstructured":"Al-Salami H, Mamo JC, Mooranian A.;et al. Long-term supple-mentation of microencapsulated ursodeoxycholic acid prevents hy-pertension in a mouse model of insulin resistance. experimental and clinical endocrinology and diabetes: official journal, german society of endocrinology. German Diabetes Association. 2017; 125(1): 28-32","journal-title":"..German Diabetes Association"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"588","DOI":"10.3109\/21691401.2014.971806","volume":"44(2)","author":"Mooranian,A.","year":"2016","unstructured":"Mooranian A, Negrulj R, Chen-Tan N.;et al. Advanced bile acid-based multi-compartmental microencapsulated pancreatic \u00df-cells integrating a polyelectrolyte-bile acid formulation, for diabetes treatment. Artif Cells Nanomed Biotechnol. 2016; 44(2): 588-95. http:\/\/dx.doi.org\/10.3109\/21691401.2014.971806 PMID: 25358121","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.3109\/21691401.2015.1069299","volume":"44(7)","author":"Mooranian,A.","year":"2016","unstructured":"Mooranian,A.; Negrulj,R.; Arfuso,F.; Al-Salami,H. Multicompart-mental, multilayered probucol microcapsules for diabetes mellitus: Formulation characterization and effects on production of insulin and inflammation in a pancreatic \u00df-cell line. Artif Cells Nanomed Biotechnol. 2016; 44(7): 1642-53. http:\/\/dx.doi.org\/10.3109\/21691401.2015.1069299 PMID: 26377035","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s12247-016-9248-7","volume":"11(2)","author":"Mooranian,A.","year":"2016","unstructured":"Mooranian,A.; Negrulj,R.; Al-Salami,H. Alginate-deoxycholic Acid Interaction and Its impact on pancreatic B-cells and insulin secre-tion and potential treatment of type 1 diabetes. J Pharm Innov. 2016; 11(2): 156-61. http:\/\/dx.doi.org\/10.1007\/s12247-016-9248-7","journal-title":"J Pharm Innov"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1007\/s11095-016-1863-y","volume":"33(5)","author":"Mooranian,A.","year":"2016","unstructured":"Mooranian,A.; Negrulj,R.; Al-Salami,H. The influence of stab ilized deconjugated ursodeoxycholic acid on polymer-hydrogel system of transplantable NIT-1 cells. Pharm Res. 2016; 33(5): 1182-90. http:\/\/dx.doi.org\/10.1007\/s11095-016-1863-y PMID: 26818840","journal-title":"Pharm Res"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s13346-015-0248-9","volume":"5(5)","author":"Mooranian,A.","year":"2015","unstructured":"Mooranian,A.; Negrulj,R.; Arfuso,F.; Al-Salami,H. The effect of a tertiary bile acid, taurocholic acid, on the morphology and physical characteristics of microencapsulated probucol: potential applica-tions in diabetes: a characterization study. Drug Deliv Transl Res. 2015; 5(5): 511-22. http:\/\/dx.doi.org\/10.1007\/s13346-015-0248-9 PMID: 26242686","journal-title":"Drug Deliv Transl Res"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3109\/02652048.2014.958204","volume":"32(2)","author":"Mooranian,A.","year":"2015","unstructured":"Mooranian A, Negrulj R, Al-Sallami HS.;et al. Release and swel-ling studies of an innovative antidiabetic-bile acid microencapsu-lated formulation, as a novel targeted therapy for diabetes treat-ment. J Microencapsul. 2015; 32(2): 151-6. http:\/\/dx.doi.org\/10.3109\/02652048.2014.958204 PMID: 25265061","journal-title":"J Microencapsul"},{"key":"ref=33","first-page":"1673","volume":"8","author":"Mooranian,A.","year":"2014","unstructured":"Mooranian,A.; Negrulj,R.; Chen-Tan,N.; Watts,GF.; Arfuso,F.; Al-Salami,H. An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid)  as a permea-tion enhancer. Drug Des Devel Ther. 2014; 8: 1673-83. PMID: 25302020","journal-title":"Drug Des Devel Ther"},{"key":"ref=34","first-page":"1221","volume":"8","author":"Mooranian,A.","year":"2014","unstructured":"Mooranian A, Negrulj R, Chen-Tan N.;et al. Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probu-col. Drug Des Devel Ther. 2014; 8: 1221-30. PMID: 25246766","journal-title":"Drug Des Devel Ther"},{"key":"ref=35","first-page":"1003","volume":"8","author":"Mooranian,A.","year":"2014","unstructured":"Mooranian A, Negrulj R, Chen-Tan N.;et al. Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: a characterization study. Drug Des Devel Ther. 2014; 8: 1003-12. PMID: 25114507","journal-title":"Drug Des Devel Ther"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2147\/JIR.S65979","volume":"7","author":"Fakhoury,M.","year":"2014","unstructured":"Fakhoury,M.; Negrulj,R.; Mooranian,A.; Al-Salami,H. Inflammatory bowel disease: clinical aspects and treatments. J Inflamm Res. 2014; 7: 113-20. http:\/\/dx.doi.org\/10.2147\/JIR.S65979 PMID: 25075198","journal-title":"J Inflamm Res"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/BF01313581","volume":"26(5)","author":"Meinders,AE.","year":"1981","unstructured":"Meinders,AE.; Van Berge,Henegouwen,GP.; Willekens,FL.; Schwerzel,AL.; Ruben,A.; Huybregts,AW. Biliary lipid and bile acid composition in insulin-dependent diabetes mellitus. Arguments for increased intestinal bacterial bile acid degradation. Dig Dis Sci. 1981; 26(5): 402-8. http:\/\/dx.doi.org\/10.1007\/BF01313581 PMID: 7018861","journal-title":"Dig Dis Sci"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/0006-2944(84) 90021-8","volume":"31(2)","author":"Wey,HE.","year":"1984","unstructured":"Wey,HE.; Yunker,RL.; Harris,P.; Subbiah,MT. Effect of streptozoto-cin-induced diabetes in neonatal rat on bile acid pool changes in adult life: selective sensitivity in females. Biochem Med. 1984; 31(2): 167-73. http:\/\/dx.doi.org\/10.1016\/0006-2944(84) 90021-8 PMID: 6372789","journal-title":"Biochem Med"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1177\/0004563212473450","volume":"50(Pt 4)","author":"Vincent,RP.","year":"2013","unstructured":"Vincent RP, Omar S, Ghozlan S.;et al. Higher circulating bile acid concentrations in obese patients with type 2 diabetes. Ann Clin Biochem. 2013; 50(Pt 4): 360-4. http:\/\/dx.doi.org\/10.1177\/0004563212473450 PMID: 23771134","journal-title":"Ann Clin Biochem"},{"key":"ref=40","author":"Sansome,DJ.","unstructured":"Sansome,DJ.; Xie,C.; Veedfald,S.; Horowitz,M.; Rayner,CK.; Wu,T. Mechanism of glucose-lowering by metformin in type 2 diabetes: Role of bile acids. Diabetes, Obesity and Metabolism.n\/a(n\/a).","journal-title":"Diabetes, Obesity and Metabolism."},{"key":"ref=41","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2013.05.007","author":"Finelli,C.","unstructured":"Finelli,C.; Sommella,L.; Gioia,S.; La Sala,N.; Tarantino,G. S hould visceral fat be reduced to increase longevity? Ageing Res Rev. 2013; 12(4): 996-1004. http:\/\/dx.doi.org\/10.1016\/j.arr.2013.05.007 PMID: 23764746","journal-title":"Ageing Res Rev"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1111\/1753-0407.12956","volume":"11(12)","author":"Li,W.","year":"2019","unstructured":"Li W, Liu R, Li X.;et al. Saxagliptin alters bile acid profiles and yields metabolic benefits in drug-na\u00efve overweight or obese type 2 diabetes patient. J Diabetes. 2019; 11(12): 982-92. http:\/\/dx.doi.org\/10.1111\/1753-0407.12956 PMID: 31141297","journal-title":"J Diabetes"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.bbalip.2014.04.008","volume":"1851(1)","author":"Qi,Y.","year":"2015","unstructured":"Qi Y, Jiang C, Cheng J.;et al. Bile acid signaling in lipid metabo-lism: metabolomic and lipidomic analysis of lipid and bile acid markers linked to anti-obesity and anti-diabetes in mice. Biochim Biophys Acta. 2015; 1851(1): 19-29. http:\/\/dx.doi.org\/10.1016\/j.bbalip.2014.04.008 PMID: 24796972","journal-title":"Biochim Biophys Acta"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"34070.","DOI":"10.1038\/srep34070","volume":"6","author":"Hou,W.","year":"2016","unstructured":"Hou W, Meng X, Zhao W.;et al. Elevated first-trimester total bile acid is associated with the risk of subsequent gestational diabetes. Sci Rep. 2016; 6: 34070. http:\/\/dx.doi.org\/10.1038\/srep34070 PMID: 27667090","journal-title":"Sci Rep"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.cca.2016.05.026","volume":"459","author":"Gao,J.","year":"2016","unstructured":"Gao J, Xu B, Zhang X.;et al. Association between serum bile acid profiles and gestational diabetes mellitus: A targeted metabolomics study. Clin Chim Acta. 2016; 459: 63-72. http:\/\/dx.doi.org\/10.1016\/j. cca.2016.05.026 PMID: 27246871","journal-title":"Clin Chim Acta"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3181\/00379727-197-43272","volume":"197(4)","author":"Batzri,S.","year":"1991","unstructured":"Batzri,S.; Harmon,JW.; Schweitzer,EJ.; Toles,R. Bile acid accumula-tion in gastric mucosal cells. Proc Soc Exp Biol Med. 1991; 197(4): 393-9. http:\/\/dx.doi.org\/10.3181\/00379727-197-43272 PMID: 1871149","journal-title":"Proc Soc Exp Biol Med"},{"key":"ref=47","author":"Kobayashi,Y.","unstructured":"Kobayashi Y, Hara N, Sugimoto R.;et al. The associations between circulating bile acids and the muscle. ume in patients with non-alcoholic fatty liver disease (NAFLD) . Intern Med. 2017; 56(7): 755-62. http:\/\/dx.doi.org\/10.2169\/internalmedicine.56.7796 PMID: 28381740"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1042\/cs0610773","volume":"61(6)","author":"Corbett,CL.","year":"1981","unstructured":"Corbett,CL.; Bartholomew,TC.; Billing,BH.; Summerfield,JA. Uri-nary excretion of bile acids in cholestasis: evidence for renal tubu-lar secretion in man. Clin Sci (Lond). 1981; 61(6): 773-80. http:\/\/dx.doi.org\/10.1042\/cs0610773 PMID: 7297039","journal-title":"Clin Sci (Lond)"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1042\/cs0520051","volume":"52(1)","author":"Summerfield,JA.","year":"1977","unstructured":"Summerfield,JA.; Cullen,J.; Barnes,S.; Billing,BH. Evidence for renal control of urinary excretion of bile acids and bile acid sul-phates in the cholestatic syndrome. Clin Sci Mol Med. 1977; 52(1): 51-65. http:\/\/dx.doi.org\/10.1042\/cs0520051 PMID: 606464","journal-title":"Clin Sci Mol Med"},{"key":"ref=50","author":"Houten,SM.","unstructured":"Houten,SM.; Watanabe,M.; Auwerx,J. Endocrine functions of bile acids. EMBO J 2006; 25(7): 1419-25. http:\/\/dx.doi.org\/10.1038\/sj.emboj.7601049 PMID: 16541101.","journal-title":"EMBO J"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"751","DOI":"10.2165\/00003088-200241100-00005","volume":"41(10)","author":"Roberts,MS.","year":"2002","unstructured":"Roberts,MS.; Magnusson,BM.; Burczynski,FJ.; Weiss,M. Enterohe-patic circulation: physiological, pharmacokinetic and clinical im-plications. Clin Pharmacokinet. 2002; 41(10): 751-90. http:\/\/dx.doi.org\/10.2165\/00003088-200241100-00005 PMID: 12162761","journal-title":"Clin Pharmacokinet"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/BF03190984","volume":"32(1)","author":"Mikov,M.","year":"2007","unstructured":"Mikov M, Boni NS, Al-Salami H.;et al. Bioavailability and hypo-glycemic activity of the semisynthetic bile acid salt, sodium 3alpha, 7alpha-dihydroxy-12-oxo-5beta-cholanate, in healthy and diabetic rats. Eur J Drug Metab Pharmacokinet. 2007; 32(1): 7-12. http:\/\/dx.doi.org\/10.1007\/BF03190984 PMID: 17479538","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.toxlet.2014.04.001","volume":"228(1)","author":"Woolbright,BL.","year":"2014","unstructured":"Woolbright BL, Li F, Xie Y.;et al. Lithocholic acid feeding results in direct hepato-toxicity independent of neutrophil function in mice. Toxicol Lett. 2014; 228(1): 56-66. http:\/\/dx.doi.org\/10.1016\/j.toxlet.2014.04.001 PMID: 24742700","journal-title":"Toxicol Lett"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1194\/jlr.M 031773","volume":"53(12)","author":"Matsubara,T.","year":"2012","unstructured":"Matsubara T, Tanaka N, Sato M.;et al. TGF-\u00df-SMAD3 signaling mediates hepatic bile acid and phospholipid metabolism following lithocholic acid-induced liver injury. J Lipid Res. 2012; 53(12): 2698-707. http:\/\/dx.doi.org\/10.1194\/jlr.M 031773 PMID: 23034213","journal-title":"J Lipid Res"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1007\/s12195-016-0441-z","volume":"9(4)","author":"Mooranian,A.","year":"2016","unstructured":"Mooranian,A.; Negrulj,R.; Jamieson,E.; Morahan,G.; Al-Salami,H. Biological assessments of encapsulated pancreatic beta-cells: their potential transplantation in diabetes. Cell Mol Bioeng. 2016; 9(4): 530-7. http:\/\/dx.doi.org\/10.1007\/s12195-016-0441-z","journal-title":"Cell Mol Bioeng"},{"key":"ref=56","first-page":"412","volume":"114(24)","author":"Melchior,H.","year":"2017","unstructured":"Melchior,H.; Kurch-Bek,D.; Mund,M. The prevalence of gestational diabetes. Dtsch Arztebl Int. 2017; 114(24): 412-8. PMID: 28669379","journal-title":"Dtsch Arztebl Int"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1515\/bchm3.1987.368.2.813","volume":"368(7)","author":"Ogura,Y.","year":"1987","unstructured":"Ogura,Y.; Ayaki,Y. Effect of diabetes on the metabolism of che-nodeoxycholic acid in isolated perfused rat liver. Biol Chem Hoppe Seyler. 1987; 368(7): 813-7. http:\/\/dx.doi.org\/10.1515\/bchm3.1987.368.2.813 PMID: 3304341","journal-title":"Biol Chem Hoppe Seyler"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1021\/jm049904b","volume":"47(18)","author":"Pellicciari,R.","year":"2004","unstructured":"Pellicciari R, Costantino G, Camaioni E.;et al. Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid. J Med Chem. 2004; 47(18): 4559-69. http:\/\/dx.doi.org\/10.1021\/jm049904b PMID: 15317466","journal-title":"J Med Chem"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"5305","DOI":"10.3892\/etm.2017.5232","volume":"14(6)","author":"Chen,X.","year":"2017","unstructured":"Chen X, Yan L, Guo Z.;et al. Chenodeoxycholic acid attenuates high-fat diet-induced obesity and hyperglycemia via the G protein-coupled bile acid receptor 1 and proliferator-activated receptor ? pathway. Exp Ther Med. 2017; 14(6): 5305-12. http:\/\/dx.doi.org\/10.3892\/etm.2017.5232 PMID: 29285057","journal-title":"Exp Ther Med"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1002\/nbm.3583","volume":"29(10)","author":"Teodoro,JS.","year":"2016","unstructured":"Teodoro,JS.; Rolo,AP.; Jarak,I.; Palmeira,CM.; Carvalho,RA. The bile acid chenodeoxycholic acid directly modulates metabolic pathways in white adipose tissue in vitro: insight into how bile ac-ids decrease obesity. NMR Biomed. 2016; 29(10): 1391-402. http:\/\/dx.doi.org\/10.1002\/nbm.3583 PMID: 27488269","journal-title":"NMR Biomed"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.tiv.2010.09.011","volume":"25(1)","author":"Khan,AA.","year":"2011","unstructured":"Khan,AA.; Chow,EC.; Porte,RJ.; Pang,KS.; Groothuis,GM. The role of lithocholic acid in the regulation of bile acid detoxication, syn-thesis, and transport proteins in rat and human intestine and liver slices. Toxicol In Vitro. 2011; 25(1): 80-90. http:\/\/dx.doi.org\/10.1016\/j.tiv.2010.09.011 PMID: 20888898","journal-title":"Toxicol In Vitro"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jconrel.2009.10.025","volume":"142(2)","author":"Chae,SY.","year":"2010","unstructured":"Chae SY, Jin CH, Shin JH.;et al. Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs. J Control Release. 2010; 142(2): 206-13. http:\/\/dx.doi.org\/10.1016\/j.jconrel.2009.10.025 PMID: 19900495","journal-title":"J Control Release"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.intimp.2012.11.017","volume":"15(2)","author":"Mart\u00ednez-Moya P","year":"2013","unstructured":"Mart\u00ednez-Moya P, Romero-Calvo I, Requena P.;et al. Dose-dependent antiinflammatory effect of ursodeoxycholic acid in ex-perimental colitis. Int Immunopharmacol. 2013; 15(2): 372-80. http:\/\/dx.doi.org\/10.1016\/j.intimp.2012.11.017 PMID: 23246254","journal-title":"Int Immunopharmacol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1016\/j.lfs.2007.02.042","volume":"80(26)","author":"Lukivskaya,O.","year":"2007","unstructured":"Lukivskaya,O.; Patsenker,E.; Buko,VU. Protective effect of ursode-oxycholic acid on liver mitochondrial function in rats with alloxan-induced diabetes: link with oxidative stress. Life Sci. 2007; 80(26): 2397-402. http:\/\/dx.doi.org\/10.1016\/j.lfs.2007.02.042 PMID: 17512017","journal-title":"Life Sci"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/cbf.1063","volume":"22(2)","author":"Lu,kivskaya,O.","year":"2004","unstructured":"Lu,kivskaya,O.; Lis,R.; Egorov,A.; Naruta,E.; Tauschel,HD.; Buko,VU. The protective effect of ursodeoxycholic acid in alloxan-induced diabetes. Cell Biochem Funct. 2004; 22(2): 97-103. http:\/\/dx.doi.org\/10.1002\/cbf.1063 PMID: 15027098","journal-title":"Cell Biochem Funct"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.2165\/00003495-200767100-00001","volume":"67(10)","author":"Staels,B.","year":"2007","unstructured":"Staels,B.; Kuipers,F. Bile acid sequestrants and the treatment of type 2 diabetes mellitus. Drugs. 2007; 67(10): 1383-92. http:\/\/dx.doi.org\/10.2165\/00003495-200767100-00001 PMID: 17600387","journal-title":"Drugs"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.jdiacomp.2017.01.011","volume":"31(5)","author":"Hansen,M.","year":"2017","unstructured":"Hansen,M.; Sonne,DP.; Mikkelsen,KH.; Gluud,LL.; Vilsb\u00f8ll,T.; Knop,FK. Bile acid sequestrants for glycemic control in patients with type 2 diabetes: A systematic review with meta-analysis of ran-domized controlled trials. J Diabetes Complications. 2017; 31(5): 918-27. http:\/\/dx.doi.org\/10.1016\/j.jdiacomp.2017.01.011 PMID: 28238556","journal-title":"J Diabetes Complications"}],"container-title":["Current Diabetes Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/179009","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/179009\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/179009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T16:13:56Z","timestamp":1611936836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/179009\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,11]]},"references-count":67,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,9,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389450121666200204115121","relation":{},"ISSN":["1573-3998"],"issn-type":[{"value":"1573-3998","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-09-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-12","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}